Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01805037 · MORE INFO

Limitations, agreements, and source contact

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas · Source last updated 2021-09-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The study did not meet it's accrual goal of 33 patients. The study closed due to lack of funding.
point Of Contact
email
barbara.pro@northwestern.edu
organization
Northwestern University, Feinberg School of Medicine
phone
312-695-6180
title
Barbara Pro, MD
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The study did not meet it's accrual goal of 33 patients. The study closed due to lack of funding.
point Of Contact
email
barbara.pro@northwestern.edu
organization
Northwestern University, Feinberg School of Medicine
phone
312-695-6180
title
Barbara Pro, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice